Proteomics International Laboratories (ASX:PIQ) said it developed and released a next-generation PromarkerD test system, an immunoassay-based diagnostic for the prediction of kidney function decline in adults with type 2 diabetes, according to a Monday Australian bourse filing.
The test can identify individuals at risk of diabetes-related chronic kidney disease up to four years before clinical symptoms appear, per the filing. It measures two plasma protein biomarkers, ApoA4 and CD5L, alongside age and estimated glomerular filtration rate to generate a personalized risk score.
The test identified 86% of at-risk individuals, missed by the current standard-of-care estimated glomerular filtration rate and urinary albumin-to-creatinine ratio tests. In a clinical study with 948 participants, the test showed that the high-risk PromarkerD group demonstrated 44-fold greater odds of kidney decline compared with the low-risk group.
The firm's shares fell 6% in recent trading, reaching their lowest point in over five years.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。